Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer

Investigational New Drugs

Volumn 16, Issue 3, 1998, Pages 275-278

  Mani, Sridhar ^a,c,d   Kugler, John W ^b   Knost, James A ^b   Sciortino, David F ^b   Gibbons, Joseph ^b   Garcia, Juan C ^b   Ansari, Rafat H ^b   Schilsky, Richard L ^a,b,c   Vokes, Everett E ^a,b,c  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c University of Chicago   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

150 Minutes; Colorectal cancer; Gemcitabine; Phase II

Indexed keywords

GEMCITABINE; PYRIMIDINE ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0032428290     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006100116229     Document Type: Article

References (12)

1. Busch E, Kemeny MM: Colorectal cancer: Hepatic- directed therapy - the role of surgery, regional chemotherapy, and novel modalities. Semin Oncol 22: 494-508, 1995
2. Goldberg RM, Fleming TR, Tangen CM, Moestel CG, MacDonald JS, Haller DG, Laurie JA: Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Intern Med 129: 27-35, 1998
3. Meropol NJ, Creaven PJ, Petrelli NJ: Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Semin Oncol 22: 509-524, 1995
4. Kaye SB: Gemcitabine: current status of phase I and II trials. J Clin Oncol 12: 1527-1531, 1994
5. Burris H III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Door FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997
6. Plunkett W, Huang P, Xu Y-Z, Heinmann V, Grunewald F, Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Seminars in Oncol 22: 3-10, 1995
7. Grunewald R, Abbruzzee JL, Tarassoff P, Plukett W: Saturation of 2′,2′-difluorodeoxycytidine 5′ triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27: 258-262, 1991
8. Veerman G, Ruiz van Haperen VWT, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2′,2-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 38: 335-342, 1996
9. Fosella F, Abbruzzese J, Pang A: Phase I studies of gemcitabine. Eur J Cancer 29: 2199, 1993
10. Ruiz van Haperen VWT, Du M, Ayres M, Ramakrishna P, Gavel D, Wolff R, Lenzi R, Abbruzzese JL, Plunkett W: Accumulation of gemcitabine triphosphate in cells during high-dose therapy: gemcitabine dose and rate dependence. Proc Amer Assoc Cancer Res 39: 187, 1998
11. Miller AB, Hoogstraten B, Statquet M: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
12. Moore DF, Pazdur F, Daugherty K, Tarassoff P, Abbruzzese JL: Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 10: 323-325, 1992